Published in Br J Pharmacol on December 01, 1992
Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest (1997) 4.92
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
Nitric oxide synthase activity in human breast cancer. Br J Cancer (1995) 2.22
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia (1999) 1.47
Differential Contribution of Acute and Chronic Inflammation to the Development of Murine Mammary 4T1 Tumors. PLoS One (2015) 1.42
Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol (1997) 1.31
Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer (1999) 1.29
Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia (2000) 1.20
Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res (2009) 1.19
Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol (1997) 1.13
Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des (2010) 1.05
Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis. FEBS Lett (2007) 1.01
Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat Rev Drug Discov (2015) 0.96
NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br J Cancer (1996) 0.95
Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer (2000) 0.95
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia (2008) 0.92
The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer (1998) 0.92
Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer (1997) 0.90
Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res (2003) 0.86
Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas. Neuro Oncol (2010) 0.85
Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia. Asian J Androl (2010) 0.85
Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer (1999) 0.84
Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer (1995) 0.84
Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol (2005) 0.84
Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. Br J Cancer (1996) 0.83
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer Suppl (1996) 0.80
Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer (2000) 0.80
Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer (1996) 0.80
Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors. Mediators Inflamm (2009) 0.78
17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br J Cancer (2002) 0.78
Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br J Cancer (1997) 0.77
A Nitric Oxide Storage and Transport System that Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity. J Biol Chem (2016) 0.76
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther (1985) 9.91
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1985) 7.36
Metastasis results from preexisting variant cells within a malignant tumor. Science (1977) 6.47
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4. FEBS Lett (1989) 2.10
Arginine metabolism in wounds. Am J Physiol (1988) 1.81
The L-arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages. J Leukoc Biol (1988) 1.72
Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res (1991) 1.64
Quantitative in-vivo studies on angiogenesis in a rat sponge model. Br J Exp Pathol (1987) 1.46
Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res (1983) 1.00
An evaluation of the response of the microvasculature in tumors in C3H mice to vasoactive drugs. Bibl Anat (1977) 0.95
Modification of tumour blood flow--a review. Int J Radiat Biol (1991) 0.93
Arginase in human urogenital tumors. Gan (1972) 0.82
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Biological diversity in metastatic neoplasms: origins and implications. Science (1982) 3.95
A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer (1987) 3.80
Simulation technology for health care professional skills training and assessment. JAMA (1999) 3.49
The biology of cancer invasion and metastasis. Adv Cancer Res (1978) 2.94
Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature (1980) 2.69
Early onset of breast cancer in a group of British black women. Br J Cancer (2008) 2.47
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol (1979) 2.42
In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res (1980) 2.40
Inhibition of release of prostaglandins as an explanation of some of the actions of anti-inflammatory corticosteroids. Nature (1975) 2.33
Release of mediators of anaphylaxis: inhibition of prostaglandin synthesis and the modification of release of slow reacting substance of anaphylaxis and histamine. Br J Pharmacol (1978) 2.20
Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res (1984) 2.13
A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst (1984) 2.08
BEME Guide No. 1: Best Evidence Medical Education. Med Teach (1999) 2.01
Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res (1980) 1.97
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child (1993) 1.94
E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol (1993) 1.89
Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax (1984) 1.71
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer (2001) 1.64
Interaction between the release of SRS-A and of prostaglandins [proceedings]. Br J Pharmacol (1976) 1.63
Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol (2005) 1.61
Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J Pathol (1993) 1.61
Release of catecholamines in the guinea-pig by substances involved in anaphylaxis. Nature (1967) 1.59
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res (1990) 1.51
Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res (1993) 1.50
Platelet activating factor does not cause a reproducible increase in bronchial responsiveness in normal man. Clin Exp Allergy (1990) 1.49
Slow-reacting substance of anaphylaxis: purification and characterisation. FEBS Lett (1978) 1.48
The release of spasmogenic substances from human chopped lung tissue and its inhibition. Br J Pharmacol (1973) 1.48
The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. Prostaglandins (1981) 1.40
The release of rabbit aorta contracting substance (RCS) from chopped lung and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1970) 1.38
An international virtual medical school (IVIMEDS): the future for medical education? Med Teach (2002) 1.38
Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer. Br J Cancer (1986) 1.36
Inhibition by glucocorticoids of prostaglandin release from adipose tissue in vitro. Br J Pharmacol (1977) 1.35
Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J Virol (1997) 1.34
Degradation of porstaglandin F2alpha in the human pulmonary circulation. Thorax (1976) 1.34
Prostaglandin inactivation in guinea-pig lung and its inhibition. Br J Pharmacol (1974) 1.32
Slow reacting substances (SRSs): the structure identification of SRSs from rat basophil leukaemia (RBL-1) cells. Prostaglandins (1980) 1.32
Antagonism by fenamates and like-acting drugs of bronchoconstriction induced by bradykinin or antigen in the guinea-pig. Br J Pharmacol (1968) 1.32
Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J Invest Dermatol (2008) 1.29
Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res (1994) 1.27
Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer (1995) 1.26
'Seed and soil' revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev (1982) 1.25
Comparative bioassay of prostaglandin E2 and its three pulmonary metabolites. Br J Pharmacol (1975) 1.25
Effect of sulfonation on the cell and tissue distribution of the photosensitizer aluminum phthalocyanine. Cancer Res (1990) 1.24
Formation and actions of leukotrienes. Physiol Rev (1984) 1.24
AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer (2001) 1.24
The mechanism of action of leukotrienes C4 and D4 in guinea-pig isolated perfused lung and parenchymal strips of guinea pig, rabbit and rat. Prostaglandins (1981) 1.22
Mechanisms of tumour metastasis. Eur J Cancer (1998) 1.22
Comparative studies on immunologically and non-immunologically produced slow-reacting substances from man, guinea-pig and rat. Br J Pharmacol (1979) 1.21
Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol (1986) 1.20
Mechanisms of inhibition of phospholipase A2. Biochem Pharmacol (1980) 1.18
Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol (2001) 1.18
The release of prostaglandins and thromboxanes from guinea-pig lung by slow reacting substance of anaphylaxis, and its inhibition. Br J Pharmacol (1978) 1.18
Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp (1998) 1.18
Stimulation of arachidonic acid metabolism and generation of thromboxane A2 by leukotrienes B4, C4 and D4 in guinea-pig lung in vitro. Br J Pharmacol (1982) 1.17
Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis (1987) 1.17
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res (1991) 1.16
Tissue uptake, distribution, and potency of the photoactivatable dye chloroaluminum sulfonated phthalocyanine in mice bearing transplantable tumors. Cancer Res (1988) 1.15
The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J Biol Chem (2000) 1.14
Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst (1985) 1.14
Use of charge coupled device camera for imaging of intracellular phthalocyanines. Photochem Photobiol (1989) 1.13
Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin. J Cell Sci (1995) 1.13
Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut (2008) 1.12
Biological and experimental consequences of the zonal composition of solid tumors. Cancer Res (1981) 1.10
Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol (1990) 1.10
The action of chemically pure SRS-A on the microcirculation in vivo. Prostaglandins (1980) 1.09
Mechanisms of metastasis. Crit Rev Oncol Hematol (1997) 1.09
Effectiveness of a computer-based system to teach bedside cardiology. Acad Med (1999) 1.09
Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer (1998) 1.08
The actions of leukotrienes C4 and D4 on guinea-pig isolated hearts. Br J Pharmacol (1982) 1.07
Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res (1996) 1.07
Integrin expression in human melanoma cell lines: heterogeneity of vitronectin receptor composition and function. Int J Cancer (1991) 1.06
The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci (1999) 1.06
The Liang Bua faunal remains: a 95k.yr. sequence from Flores, East Indonesia. J Hum Evol (2008) 1.06
The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci (1998) 1.06
Pharmacology of leukotrienes. Br Med Bull (1983) 1.05
In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res (1993) 1.04
The implications of tumor heterogeneity for studies on the biology of cancer metastasis. Biochim Biophys Acta (1981) 1.04
Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res (1980) 1.04
Slow-reacting substance of anaphylaxis: studies on purification and characterisation. Agents Actions Suppl (1979) 1.03
Release of vaso-active substances from lungs by injection of particles. Br J Pharmacol (1970) 1.02
Mononuclear phagocyte adherence in the presence of laminin. A possible marker of cellular differentiation. Exp Cell Res (1983) 1.01
The role of the epithelium in modulating the responses of guinea-pig trachea induced by bradykinin in vitro. Br J Pharmacol (1990) 1.01
Inhibition of the pulmonary inactivation of prostaglandins in vivo by di-4-phloretin phosphate. Br J Pharmacol (1975) 1.00
alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol (2001) 1.00
Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res (1981) 0.99
Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay. Br J Clin Pharmacol (1987) 0.99
The effect of histamine antagonists on antigen-induced contractions of sensitized human bronchus in vitro [proceedings]. Br J Pharmacol (1977) 0.98
Metastasis and angiogenesis. Acta Oncol (1990) 0.98
Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res (1991) 0.98
Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique. Cancer Res (1989) 0.98
The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol (1996) 0.97
The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol (2001) 0.97
Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res (1981) 0.97
Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol (1987) 0.96
Identification of genes controlling metastatic behaviour. Br J Cancer (1991) 0.96
The effectiveness of immediate feedback during the objective structured clinical examination. Med Educ (1989) 0.95